Clinical Research Directory

Inclusion Criteria: * Must provide written informed consent * Female at 18-80 years of age * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 * With anticipated survival of at least 36 months * Pathologically confirmed invasive breast cancer with clinical stage of T1-4N0-1M0 * Received standard NAT for BC (including either neoadjuvant chemotherapy or neoadjuvant targeted therapy, or a combination) * Have willingness to take the 18F-FAPI PET/CT imaging * With adequate organ function (neutrophil count ≥ 1.5 × 10⁹/L; platelet count ≥ 90 × 10⁹/L; hemoglobin ≥ 90 g/L; total bilirubin ≤ 1.5 × upper limit of normal \[ULN\]; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN; blood urea nitrogen (BUN) and serum creatinine (Cr) ≤ 1.5 × ULN; international normalized ratio (INR) ≤ 1.5 × ULN, activated partial thromboplastin time (APTT) ≤ 1.5 × ULN). Exclusion Criteria: * Evidence of distant metastatic disease (M1) * Pregnant or lactating women * Failure to complete the planned NAT * Prior surgical intervention in the ipsilateral axilla * Diagnosis of any other malignancy within the past 5 years (exceptions: adequately treated non-melanoma skin cancer, cervical carcinoma in situ, papillary thyroid cancer) * Known hypersensitivity to the FAPI tracer or any excipients * With any serious uncontrolled medical condition that would make the patient unsuitable for surgery or PET/CT (e.g. unstable cardiac disease, severe claustrophobia unresponsive to anxiolytics, renal failure preventing CT contrast if needed) * Failure to lie still for imaging (about 20-30 minutes) or adhere to follow-up due to psychiatric, cognitive, or social reasons.